As of the latest Form 4 filed May 22, 2026.
What ICU Medical Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 62 most recent filings for ICUI.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | 2026-05-22 | Woolson Daniel President | SSale | −2.12K | $132.21 | $281K | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-14 | Sanzone Virginia Ruth VP, General Counsel | SSale | −2.45K | $124.08 | $304K | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-13 | Hernandez Laurie Director | MExercise | +1.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-13 | Greenberg David C. Director | MExercise | +1.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-13 | Abbey Donald Director | MExercise | +1.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-13 | KENNEDY KOLLEEN T Director | MExercise | +1.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-13 | Hoffmeister David F Director | MExercise | +1.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-13 | FINNEY ELISHA W Director | MExercise | +1.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-12 | Greenberg David C. Director | SSale | −2.42K | $122.91 | $298K | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-12 | Greenberg David C., Director | MExercise | +2.42K | $101.06 | $245K | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-25 | Abbey Donald Director | JOther | −704.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Sousa Ben Chief Information Officer | FTax | −718.00 | $125.85 | $90.4K | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Sousa Ben, Chief Information Officer | MExercise | +1.30K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Bonnell Brian Michael Chief Financial Officer | FTax | −1.79K | $125.85 | $226K | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Bonnell Brian Michael, Chief Financial Officer | MExercise | +3.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Bonnell Brian Michael, Chief Financial Officer | FTax | −5.80K | $125.85 | $730K | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Bonnell Brian Michael, Chief Financial Officer | MExercise | +11.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Voigtlander Christian B. Chief Operating Officer | FTax | −1.79K | $125.85 | $226K | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Voigtlander Christian B., Chief Operating Officer | MExercise | +3.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Voigtlander Christian B., Chief Operating Officer | FTax | −6.30K | $125.85 | $793K | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Voigtlander Christian B., Chief Operating Officer | MExercise | +11.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Woolson Daniel VP, GM-Infusion Capital | FTax | −1.29K | $125.85 | $163K | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Woolson Daniel, VP, GM-Infusion Capital | MExercise | +2.92K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Sanzone Virginia Ruth VP, General Counsel | FTax | −897.00 | $125.85 | $113K | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Sanzone Virginia Ruth, VP, General Counsel | MExercise | +1.62K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Sanzone Virginia Ruth, VP, General Counsel | FTax | −3.15K | $125.85 | $396K | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Sanzone Virginia Ruth, VP, General Counsel | MExercise | +5.70K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Jain Vivek Chairman and CEO | FTax | −2.69K | $125.85 | $339K | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Jain Vivek, Chairman and CEO | MExercise | +4.87K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Jain Vivek, Chairman and CEO | FTax | −9.45K | $125.85 | $1.19M | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Jain Vivek, Chairman and CEO | MExercise | +17.1K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Sousa Ben Chief Information Officer | FTax | −529.00 | $132.00 | $69.8K | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Sousa Ben, Chief Information Officer | MExercise | +957.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Sousa Ben, Chief Information Officer | FTax | −3.97K | $132.00 | $524K | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Sousa Ben, Chief Information Officer | MExercise | +7.18K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Bonnell Brian Michael Chief Financial Officer | FTax | −39.7K | $132.00 | $5.24M | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Bonnell Brian Michael, Chief Financial Officer | MExercise | +71.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Voigtlander Christian B. Chief Operating Officer | FTax | −39.7K | $132.00 | $5.24M | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Voigtlander Christian B., Chief Operating Officer | MExercise | +71.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Woolson Daniel VP, GM-Infusion Capital | FTax | −630.00 | $132.00 | $83.2K | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Woolson Daniel, VP, GM-Infusion Capital | MExercise | +2.15K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Woolson Daniel, VP, GM-Infusion Capital | FTax | −6.88K | $132.00 | $908K | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Woolson Daniel, VP, GM-Infusion Capital | MExercise | +16.1K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Sanzone Virginia Ruth VP, General Counsel | FTax | −1.76K | $132.00 | $233K | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Sanzone Virginia Ruth, VP, General Counsel | MExercise | +3.19K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Sanzone Virginia Ruth, VP, General Counsel | FTax | −13.2K | $132.00 | $1.75M | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Sanzone Virginia Ruth, VP, General Counsel | MExercise | +23.9K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Jain Vivek Chairman and CEO | FTax | −59.5K | $132.00 | $7.85M | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-08 | Jain Vivek, Chairman and CEO | MExercise | +108K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-07 | Sousa Ben Chief Information Officer | FTax | −782.00 | $132.00 | $103K | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-07 | Sousa Ben, Chief Information Officer | MExercise | +1.41K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-07 | Bonnell Brian Michael Chief Financial Officer | FTax | −1.26K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-07 | Bonnell Brian Michael, Chief Financial Officer | MExercise | +3.52K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-07 | Voigtlander Christian B. Chief Operating Officer | FTax | −1.95K | $132.00 | $257K | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-07 | Voigtlander Christian B., Chief Operating Officer | MExercise | +3.52K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-07 | Woolson Daniel VP, GM-Infusion Capital | FTax | −702.00 | $132.00 | $92.7K | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-07 | Woolson Daniel, VP, GM-Infusion Capital | MExercise | +1.58K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-07 | Sanzone Virginia Ruth VP, General Counsel | FTax | −1.30K | $132.00 | $171K | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-07 | Sanzone Virginia Ruth, VP, General Counsel | MExercise | +2.35K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-07 | Jain Vivek Chairman and CEO | FTax | −2.92K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-07 | Jain Vivek, Chairman and CEO | MExercise | +5.28K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-11-25 | 2025-11-25 | Woolson Daniel VP, GM-Infusion Capital | SSale | −2.90K | $152.35 | $441K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ICUI’s full analysis or the market-wide insider trading feed. The tabs above jump to ICUI’s other SEC data.
Source: SEC Form 4 filings for ICUI, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.